Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07399587 · ClinicalTrials.gov registry record · Phase 2
Optimizing HFrEF Patients Using BaroStim and CardioMems
A Phase 2 study of Heart Failure NYHA Class III, sponsored by Northwell Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT07399587: Recruiting Phase 2 study of Heart Failure NYHA Class III, sponsored by Northwell Health.
NCT07399587 is a Phase 2 study of Heart Failure NYHA Class III that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 15 participants, below the 844-participant average among 9 other Heart Failure NYHA Class III trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07399587, a Phase 2 study of Heart Failure NYHA Class III, is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to utilize CardioMems (measurement of pulmonary artery diastolic pressure) to assess BaroStim. At the time of CardioMems insertion, patients will be screened for candidacy to receive a BaroStim device. Patients will be followed for 3 months after the CardioMems insertion before undergoing insertion of a Barostim. Patients who have undergone a CardioMems, will be eligible for enrollment after 3 months of medication management and optimization. Patients will be followed for 1 year after insertion of Barostim.
Primary Outcome
Pulmonary Artery Diastolic Pressure as Measured by CardioMems Device
Conditions Studied
Interventions
- DEVICE BaroStim
Study Locations (1)
New York
- Peconic Bay Medical Center - Riverhead
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-01-17 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 2 |
What NCT07399587 shows while recruiting
NCT07399587 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 844-participant average among 9 other Heart Failure NYHA Class III trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Heart Failure NYHA Class III appearing as the primary indexed condition, and to 1 intervention - of which BaroStim is the first listed.
NCT07399587 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07399587 about?
NCT07399587 is a clinical study titled "Optimizing HFrEF Patients Using BaroStim and CardioMems". The goal of this study is to utilize CardioMems (measurement of pulmonary artery diastolic pressure) to assess BaroStim. At the time of CardioMems insertion, patients will be screened for candidacy to receive a BaroStim device. Patients will be followed for 3 months after the CardioMems insertion be...
What is the current status of trial NCT07399587?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2025-01-17. Estimated completion is 2029-12-31.
What conditions does trial NCT07399587 study?
This clinical trial studies the following conditions: Heart Failure NYHA Class III.
What interventions are being tested in trial NCT07399587?
The interventions under investigation include: BaroStim (DEVICE).
Who is sponsoring clinical trial NCT07399587?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07399587 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure NYHA Class III
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07399587's enrollment target sits among peer trials
15 10th of 9 the lowest of 9 other Heart Failure NYHA Class III trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure NYHA Class III trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Real World Effectiveness of the Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Heart Failure
RECRUITING
-
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
RECRUITING · NA
-
Promoting Well-being and Health in Heart Failure
RECRUITING · NA
-
An Early Feasibility Study Evaluation of an Implant Free Interatrial Shunt to Improve Heart Failure
RECRUITING · NA
-
Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease
RECRUITING · Phase 1
-
Sustaining Home Heart Failure Palliative Care in Rural Appalachia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI